AbbVie (NYSE:ABBV) Stock Price Up 2.6% – Time to Buy?

AbbVie Inc. (NYSE:ABBV)’s share price traded up 2.6% during trading on Tuesday . The company traded as high as $266.92 and last traded at $263.49. Approximately 6,790,808 shares changed hands during mid-day trading, a decline of 4% from the average daily volume of 7,037,222 shares. The stock had previously closed at $256.91.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi and Rinvoq remain key growth engines. The two drugs are reportedly growing at more than 20% and have increasingly replaced Humira as AbbVie’s primary growth drivers, supporting the company’s long-term revenue outlook. Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
• Positive Sentiment: Income and guidance support the bullish case. Commentary ahead of earnings highlights AbbVie’s approximately 2.62% dividend yield and raised earnings guidance, offering investors a combination of income and expected growth. 3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st
• Positive Sentiment: RINVOQ clinical evidence is advancing. AbbVie completed a real-world effectiveness study of RINVOQ in psoriatic arthritis, potentially strengthening the drug’s commercial and medical support, although the full investment impact depends on the results. AbbVie Wraps Up Real-World RINVOQ Study in Psoriatic Arthritis
• Neutral Sentiment: ABBV-722 reached an early clinical milestone. AbbVie reported progress in the Phase 1 trial of ABBV-722, but early safety data are not yet sufficient to establish the drug’s commercial prospects. AbbVie’s ABBV-722 Phase 1 Milestone
• Neutral Sentiment: Former AbbVie executive Michael Severino was appointed CEO of Sarepta Therapeutics. The move is not expected to materially affect AbbVie’s operations, but it may draw limited attention to executive turnover. Sarepta Names Former AbbVie President as CEO
• Negative Sentiment: Earnings-related volatility is a near-term risk. Analysts caution that the recent rally may already reflect strong expectations, creating the possibility of “sell the news” pressure if second-quarter results or guidance fail to exceed forecasts. Should You Buy AbbVie Stock Hand Over Fist Before July 31?

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ABBV shares. Citigroup raised their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Royal Bank Of Canada upped their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Wells Fargo & Company upped their target price on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. raised their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $268.10.

AbbVie Stock Up 2.6%

The company has a market cap of $465.53 billion, a price-to-earnings ratio of 129.80, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30. The company’s 50-day moving average is $235.52 and its 200 day moving average is $223.11.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the previous year, the company earned $2.46 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Analysts predict that AbbVie Inc. will post 14.18 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

Institutional Trading of AbbVie

Several institutional investors have recently bought and sold shares of the business. Sunpointe LLC lifted its holdings in AbbVie by 9.9% during the second quarter. Sunpointe LLC now owns 4,063 shares of the company’s stock valued at $1,023,000 after purchasing an additional 366 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of AbbVie by 2.6% during the second quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 18,383 shares of the company’s stock worth $4,626,000 after purchasing an additional 468 shares in the last quarter. BridgePort Financial Solutions LLC purchased a new stake in shares of AbbVie during the second quarter worth about $257,000. WealthBridge Capital Management LLC raised its position in shares of AbbVie by 0.7% during the 2nd quarter. WealthBridge Capital Management LLC now owns 13,209 shares of the company’s stock worth $3,324,000 after purchasing an additional 89 shares during the last quarter. Finally, Petra Financial Advisors Inc. acquired a new position in shares of AbbVie during the 2nd quarter worth about $243,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.